

Evaluation Report for Category B, Subcategory 2.1, 2.3, 2.4, 2.6 Application

Application Number: 2021-2096
Application: New Manufacturing Concentrate (Product Chemistry) – Guarantee, Identity of Formulants, Proportion of Formulants, New Combination of Technical Grade Active Ingredients
Product: Select Plus Bulk
Registration Number: 34743
Active ingredients (a.i.): Clethodim and Quizalofop-P-ethyl
PMRA Document Number: 3428640

Purpose of Application

The purpose of this application was to register Select Plus Bulk, a manufacturing concentrate.

Chemistry Assessment

Select Plus Bulk is formulated as an emulsifiable concentrate containing clethodim and quizalofop-P-ethyl at concentrations of 240 g/L and 120 g/L, respectively. This end-use product has a density of 0.999 g/mL and pH of 4.28. The required chemistry data for Select Plus Bulk have been provided, reviewed and found to be acceptable.

Health Assessments

Select Plus Bulk is of low acute toxicity by the oral, dermal, and inhalation routes. It is moderately irritating to the eye and non-irritating to the skin. It is not a skin sensitizer.

Occupational and dietary assessments were not required for this application.

Environmental and Value Assessments

Environmental and value assessments were not required for this application.

Conclusion

The Pest Management Regulatory Agency has completed an assessment of the information provided, and has found the information acceptable to support the registration of Select Plus Bulk.

References

PMRA Document Number	Reference
3230918	2020, H1331aa Product Identity and Composition, Description of Materials Used to Produce the Product, Description of Formulation Process, Discussion of Formation of Impurities, and Certified Limits, DACO: 3.0,3.1,3.2,3.2.1,3.2.2,3.2.3,3.4.2 CBI
3230922	2020, H1331aa: Physical Properties, DACO: 3.5.1,3.5.11,3.5.12,3.5.13,3.5.15,3.5.2,3.5.3,3.5.6,3.5.7,3.5.8,3.5.9 CBI
3230924	2020, H1331aa: Storage Stability and Corrosion Characteristics, DACO: 3.5.10,3.5.14 CBI
3240017	2021, H1331aa Herbicide Product Identity and Composition, Description of the Materials Used and Formulation Process, Discussion of the Formation of Impurities, Certified Limits, and Enforcement Analytical Method, DACO: 3.0,3.1,3.2,3.3.1,3.4 CBI
3310722	2020, Additional Product Chemistry for H1331aa Herbicide, updated, DACO: 3.1.1,3.1.2,3.1.4,3.5.4,3.5.5 CBI
3310723	2022, Determination of Isomeric Ratio of R-Quizalofop-Ethyl and S-Quizalofop-Ethyl in Clethodim 240 + Quizalofop-P-Ethyl 120 g/L EC, DACO: 3.4.1 CBI
3310724	2022, Validation of Analytical Method for Determination of Active Ingredient Content of Clethodim 240 + Quizalofop-P-Ethyl 120 g/L EC, DACO: 3.4.1 CBI
3310727	2022, Specific Gravity of Clethodim 240 + Quizalofop-P-Ethyl 120 g/L EC Data, DACO: 3.5.6 CBI
3310728	2022, Accelerated Storage Stability and Corrosion Characteristics of Clethodim 240 + Quizalofop-P-Ethyl 120 g/L EC, DACO: 3.5.10 CBI
3230925	2014, Acute Oral Toxicity in Rats (<i>Rattus norvegicus</i>) With the Test Substance BR-ARY-10-13 F01 (Clethodim 240 + Quizalofop-P-Ethyl 120 EC), DACO: 4.6.1
3230926	2014, Acute Dermal Toxicity in Rats (<i>Rattus norvegicus</i>) With the Test Substance BR-ARY-10-13 F01 (Clethodim 240 + Quizalofop-P-Ethyl 120 EC), DACO: 4.6.2
3230928	2014, Acute Inhalation Toxicity Test with BR-ARY-10-13 F01 (Clethodim 240 + Quizalofop-P-Ethyl 120 EC) in Rats (<i>Rattus norvegicus</i>), DACO: 4.6.3
3230930	2014, Acute Eye Irritation/Corrosion Study in Rabbits (<i>Oryctolagus cuniculus</i>) With the Test Substance BR-ARY-10-13 F01 (Clethodim 240 + Quizalofop-P-Ethyl 120 EC), DACO: 4.6.4

PMRA Document Number	Reference
3230931	2014, Acute Dermal Irritation/Corrosion in Rabbits (<i>Oryctolagus cuniculus</i>) With the Test Substance BR-ARY-10-13 F01 (Clethodim 240 + Quizalofop-P-Ethyl 120 EC), DACO: 4.6.5
3230932	2014, Skin Sensitization in Guinea Pigs (<i>Cavia porcellus</i>) With the Test Substance BR-ARY-10-13 F01 (Clethodim 240 + Quizalofop-P-Ethyl 120 EC) (Buehler Test Method), DACO: 4.6.6

© His Majesty the King in Right of Canada, as represented by the Minister of Health Canada, 2023

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.